This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MediPoint: Total Hip Replacement - EU Analysis And Market Forecasts

NEW YORK, Sept. 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: MediPoint: Total Hip Replacement - EU Analysis and Market Forecasts http://www.reportlinker.com/p01623040/MediPoint-Total-Hip-Replacement---EU-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

MediPoint: Total Hip Replacement - EU Analysis and Market Forecasts SummaryOsteoarthritis has become a global public health concern with no cure. It is the most common form of arthritis that is primarily due to wear and tear of the joints. With the aging global population, this is an indication that is growing rapidly with the hip being one of the most common joints afflicted. While the primary indication for total hip replacement (THR) is osteoporosis, the other major indications for THR are osteonecrosis and fractures to a lesser degree. As people live longer and with younger patients also receiving implants, the revision rates for primary hip replacements are also expected to rise. Primary hip replacement has become one of the most successful surgeries, with a variety of femoral and acetabular components available from a wide selection of manufacturers. This report focuses on the total primary hip replacement market along with primary revision market. The global hip replacement market has been estimated in this report which includes France, Germany, Italy, Spain, UK. The report provides unmet needs, future adoption and compounded annual growth rates (CAGR). GlobalData's analysis shows that the hip replacement market has become a mature market where products have become commodities. The future of the market lays on the ability of manufacturers to provide implants at a very low cost while continuing to provide the same level of clinical efficacy. The product development need lies primarily in revising the resurfacing products' articulating surface with new materials rather than developing new acetabular and femoral components. Additionally the major opportunity lies within the emerging markets which are the countries that have a higher CAGR and will provide the key for growth and grabbing market share. Scope- An overview of Osteoarthritis, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized EU THR market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018. - Investigation of current and future market competition for THR- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. - Analysis of unmet needs within the market and opportunities for future players. - Technology trends evaluation to assess strength of pipeline. - An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines. - Company profiles including business description, financial overview and SWOT analysis. - Coverage of key market players. - Strategic assessment of the THR sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as Orthopedic Surgeon. Reasons to buy- Understand the trends shaping and driving the EU THR Market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in the EU THR market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. - Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. - What's the next big thing in EU THR market landscape? Identify, understand and capitalize.1 Table of Contents1 Table of Contents 71.1 List of Tables 161.2 List of Figures 262 Introduction 302.1 Catalyst 313 Disease Overview 323.1 Anatomy and Physiology 323.2 Pathophysiology 333.2.1 Overview 333.2.2 Osteoarthritis 343.2.3 Rheumatoid Arthritis 343.2.4 Post-traumatic Arthritis 353.2.5 Osteonecrosis 353.2.6 Injury 363.2.7 Bone Tumors 363.2.8 Other Diseases 363.3 Clinical Presentation 373.4 Clinical Outcomes 383.4.1 Overview 383.4.2 Conservative Therapy 413.4.3 Hip Arthroscopy 413.4.4 Hip Arthrodesis 423.4.5 Hemiarthroplasty (Partial) 433.4.6 Core Decompression 433.4.7 Hip Osteotomy 443.4.8 Resection Arthroplasty 443.4.9 Primary Total Hip Replacement 45 3.4.10 Revision Total Hip Replacement 47 3.4.11 Resurfacing Arthroplasty 48 3.4.12 Computer-Navigated Hip Replacement 493.5 Surgical Approaches 493.5.1 Anterolateral Approach 503.5.2 Posterior Approach 513.5.3 Direct Anterior Approach 523.5.4 Minimally Invasive Approaches 533.6 Epidemiology 543.6.1 EU 563.7 Economic Impact 583.7.1 EU 594 Competitive Assessment 614.1 Overview of Historical Designs 614.2 Marketed Products 624.2.1 Global Market Share 624.2.2 Primary Total Hip Replacement 644.2.3 Product Profiles by Company 655 Unmet Needs 2195.1 Long-Term Clinical Data 2195.2 Need for Continued Materials Research 2205.3 Bearings 2225.4 Refocus of Pipeline Products 2235.5 Renewal of Resurfacing 2245.6 Addressing the Learning Curve for Tier II Surgeons 2265.7 Need for Cost Containment 2285.8 Centralization 2295.9 National Joint Registry 2306 Pipeline Products 2316.1 Overview 2316.2 Primary Total Hip Pipeline Products 2326.2.1 Exactech LPI Prime Hip System 2326.2.2 EnduRo Bone-preserving Hip Stem 2336.2.3 Deltamotion Acetabular Cup System 2336.2.4 NovoSource Hip Implant 2337 Industry Overview 2347.1 Procedure Volumes 2347.1.1 EU 2357.2 Market Access 2377.2.1 EU 2387.3 Reimbursement Trends 2407.3.1 Europe 2407.4 Regulatory Issues/Recalls 2457.4.1 DePuy Hip Replacement Recall 2457.4.2 Stryker Hip Replacement Recall 2467.4.3 Smith & Nephew Recall: R3 Metal Liners of the R3 Acetabular System 2467.4.4 Zimmer Durom® Acetabular Component 2467.4.5 Biomet Hip Replacement Complications 2467.4.6 Wright Medical Conserve Hip Implant 2477.4.7 The Corin Group Metal-on-Metal Hip Resurfacing 2477.5 Mergers & Acquisitions / Key Partnerships 2487.5.1 Medtronic Acquires China Kanghui Holdings 2487.5.2 Tornier Acquires OrthoHelix Surgical Designs Inc. 2487.5.3 DePuy Orthopaedics (Johnson & Johnson) and Synthes Inc. Merge 2487.5.4 Italian Consortium 2IL Orthopaedics Ltd Acquires Corin Group 2497.5.5 Zimmer Acquires Beijing Montagne Medical Device Co. Ltd. 2497.5.6 Wright Medial Announces Agreement to Sell OrthoRecon Business to MicroPort Medical B.V. 2498 Company Profiles 2508.1 B. Braun 2508.1.1 Overview 2508.1.2 Portfolio Assessment 2518.1.3 SWOT Analysis 2518.2 Biomet Orthopedics 2528.2.1 Overview 2528.2.2 Portfolio Assessment 2538.2.3 SWOT Analysis 2568.3 Corentec Co. Ltd. 2578.3.1 Overview 2578.3.2 Portfolio Assessment 2578.3.3 SWOT Analysis 2588.4 Corin 2588.4.1 Overview 2588.4.2 Portfolio Assessment 2598.4.3 SWOT Analysis 2608.5 DePuy Synthes International 2618.5.1 Overview 2618.5.2 Portfolio Assessment 2628.5.3 SWOT Analysis 2658.6 Exactech 2658.6.1 Overview 2658.6.2 Portfolio Assessment 2668.6.3 SWOT Analysis 2688.7 Iconacy Orthopedic Implants LLC 2698.7.1 Overview 2698.7.2 Portfolio Assessment 2698.7.3 SWOT Analysis 2708.8 Implantcast GMBH 2718.8.1 Overview 2718.8.2 Portfolio Assessment 2718.8.3 SWOT Analysis 2738.9 JRI Orthopaedics 2748.9.1 Overview 2748.9.2 Portfolio Assessment 2758.9.3 SWOT Analysis 2768.10 Kyocera 2778.10.1 Overview 2778.10.2 Portfolio Assessment 2788.10.3 SWOT Analysis 2798.11 Limacorporate S.P.A 2808.11.1 Overview 2808.11.2 Portfolio Assessment 2818.11.3 SWOT Analysis 2828.12 Medacta 2838.12.1 Overview 2838.12.2 Portfolio Assessment 2848.12.3 SWOT Analysis 2858.13 Medtronic 2858.13.1 Overview 2858.13.2 Portfolio Assessment 2868.13.3 SWOT Analysis 2878.14 NovoSource Inc. 2888.14.1 Overview 2888.14.2 Portfolio Assessment 2888.14.3 SWOT Analysis 2898.15 Peter Brehm GMBH 2898.15.1 Overview 2898.15.2 Portfolio Assessment 2908.15.3 SWOT Analysis 2908.16 Serf Dedienne Santé 2918.16.1 Overview 2918.16.2 Portfolio Assessment 2928.16.3 SWOT Analysis 2938.17 Smith & Nephew 2938.17.1 Overview 2938.17.2 Portfolio Assessment 2948.17.3 SWOT Analysis 2968.18 Stelkast 2978.18.1 Overview 2978.18.2 Portfolio Assessment 2988.18.3 SWOT Analysis 2988.19 Stryker 2998.19.1 Overview 2998.19.2 Portfolio Assessment 3018.19.3 SWOT Analysis 3028.20 Tianjin Zhengtian Medical Instrument Co., Ltd. 3038.20.1 Overview 3038.20.2 Portfolio Assessment 3038.20.3 SWOT Analysis 3048.21 Tornier N.V. 3058.21.1 Overview 3058.21.2 Portfolio Assessment 3068.21.3 SWOT Analysis 3088.22 Wright Medical 3098.22.1 Overview 3098.22.2 Portfolio Assessment 3108.22.3 SWOT Analysis 3128.23 United Orthopedic Corporation 3138.23.1 Overview 3138.23.2 Portfolio Assessment 3148.23.3 SWOT Analysis 3148.24 Zimmer Holdings Inc. 3158.24.1 Overview 3158.24.2 Portfolio Assessment 3178.24.3 SWOT Analysis 3188.25 Other Companies 3199 Market Drivers, Opportunities and Barriers 3209.1 Market Drivers 3209.1.1 Prevalence Rise 3209.1.2 Expanding Indications 3229.1.3 Availability and Lack of Long-Term Clinical Data 3239.1.4 Fracture Incidence 3239.1.5 Patient Demand and Awareness 3239.2 Opportunities 3249.2.1 Revision Surgery 3249.2.2 Emerging Markets 3259.2.3 Continued Materials Research 3269.2.4 Corporate Promotions and Teaching Seminars 3269.2.5 Advancement towards Cost Reduction 3279.3 Market Barriers 3289.3.1 Market Barriers 32810 Country Outlooks & Forecasts 33210.1 EU Markets Overview 33210.2 France Market Analysis 33610.3 Germany Market Analysis 33810.4 Italy Market Analysis 34010.5 Spain Market Analysis 34110.6 UK Market Analysis 34311 Appendix 34511.1 Abbreviations 34511.2 Bibliography 34711.3 Report Methodology 36411.3.1 Overview 36411.3.2 Coverage 36411.3.3 Secondary Research 36511.3.4 Forecasting Methodology 36611.3.5 Primary Research – Key Opinion Leader Interviews 36711.3.6 Expert Panel Validation 36711.4 Physicians and Specialists Included in this Study 36811.4.1 Dr. Alessandro Aprato 36811.4.2 Dr. Fran Channa 36811.4.3 Joseph Daniel FRCS MS (Orth) 36811.4.4 Dr. Alejandro Gonzalez Della Valle 36811.4.5 Dr. Moussa Hamadouche 36811.4.6 Dr. Sheng-Li Huang and Xi-Jing He 36811.4.7 Dr. Ayumi Kaneuji 36811.4.8 Dr. Yuichi Mitani 36811.4.9 Dr. Ning Lu 369 11.4.10 Dr. Deepak Saini 369 11.4.11 Dr. Lafayette Lage 369 11.4.12 Dr. Christoph Zilkens 36911.5 About the Authors 37011.5.1 Analysts 37011.5.2 Global Head of Healthcare 37111.6 About MediPoint 37211.7 About GlobalData 37211.8 Disclaimer 372 1.1 List of TablesTable 1: Clinical Symptoms and Descriptions 37Table 2: Advantages and Disadvantages of Hip Resurfacing 48Table 3: Surgical Approaches Comparison 49Table 4: Global Prevalence of Osteoarthritis in the Major EU Markets, millions, 2010–2019 54Table 5: Direct and Indirect Costs of Arthritis 58Table 6: Top Five Products Used in the UK, 2003–2011, by Popularity, by Component 63Table 7: Bicontact Universal Hip System (B. Braun) 66Table 8: Clinical Studies Bicontact Universal Hip System (B. Braun) 67Table 9: SWOT Bicontact Universal Hip System 68Table 10: Excia Hip Stem (B. Braun) 70Table 11: Clinical Studies Excia Hip Stem (B. Braun) 71Table 12: SWOT Excia Hip Stem 71Table 13: Metha® Short Hip Stem (B. Braun) 73Table 14: Clinical Studies Metha® Short Hip Stem (B. Braun) 74Table 15: SWOT Metha® Short Hip Stem 74Table 16: TRJ Cementless Hip Endoprosthesis System (B. Braun) 76Table 17: SWOT TRJ Cementless Hip Endoprosthesis System 77Table 18: Plasmacup SC Acetabular Cup (B. Braun) 78Table 19: Balance Femoral Component (Biomet) 80Table 20: Clinical Studies Balance Femoral Component (Biomet) 80Table 21: SWOT Balance Femoral Component 81Table 22: Bi-Metric Femoral Components (Biomet) 82Table 23: Clinical Studies Bi-Metric Femoral Components (Biomet) 82Table 24: SWOT Bi-Metric Femoral Components 83Table 25: Bio-Moore II Hip System (Biomet) 84Table 26: Clinical Studies Bio-Moore II Hip System (Biomet) 84Table 27: SWOT Bio-Moore II Hip System 85Table 28: Generation 4 Polished Hip System (Biomet) 86Table 29: SWOT Generation 4 Polished Hip System 87Table 30: Integral Porous Primary Hip System (Biomet) 88Table 31: Clinical Studies Integral Porous Hip System (Biomet) 88Table 32: SWOT Integral Porous Hip System Femoral Components 89Table 33: Mallory Femoral Component (Biomet) 90Table 34: Clinical Studies Mallory Femoral Component (Biomet) 91Table 35: SWOT Mallory Femoral Component 91Table 36: Progressive Total Hip System (Biomet) 92Table 37: SWOT Progressive Total Hip System 93Table 38: Rx 90 Smooth Primary Femoral Component (Biomet) 94Table 39: SWOT Rx 90 Smooth Primary Femoral Component 94Table 40: Stanmore Hip System (Biomet) 96Table 41: Clinical Studies Stanmore Hip System (Biomet) 96Table 42: SWOT Stanmore Hip System 97Table 43: Taperloc and Balance Microplasty Hip Stems (Biomet) 98Table 44: Clinical Studies Taperloc and Balance Microplasty Hip Stems (Biomet) 99Table 45: SWOT Taperloc and Balance Microplasty Hip Stems 99Table 46: Acetabular Systems (Biomet) 100Table 47: Bencox Stems (Corentec Co. Ltd) 102Table 48: Clinical Studies Bencox Stems (Corentec Co. Ltd) 103Table 49: SWOT Bencox Stems 103Table 50: Bencox Acetabular Systems (Corentec Co. Ltd.) 104Table 51: MetaFix (Corin) 106Table 52: SWOT MetaFix 107Table 53: MiniHip (Corin) 108Table 54: SWOT MiniHip 108Table 55: MRP-Titan (Corin) 110Table 56: SWOT MRP-Titan 110Table 57: TaperFit (Corin) 112Table 58: SWOT TaperFit 112Table 59: Trinity Acetabular System (Corin) 114Table 60: Cenator Acetabular Cup (Corin) 115Table 61: Cementless Systems (DePuy Synthes) 117Table 62: Clinical Studies Cementless Systems (DePuy Synthes) 117Table 63: SWOT DePuy Synthes Cementless Systems 118Table 64: Cemented Systems (DePuy Synthes) 119Table 65: Clinical Studies Cemented Systems (DePuy Synthes) 119Table 66: SWOT DePuy Synthes Cemented Systems 119Table 67: DePuy Synthes Acetabular Systems (DePuy Synthes) 121Table 68: AcuMatch Femoral Stems (Exactech) 123Table 69: Clinical Studies AcuMatch Femoral Stems (Exactech) 123Table 70: SWOT AcuMatch Femoral Stems 124Table 71: Novation Femoral Stems (Exactech) 126Table 72: Clinical Studies Novation Femoral Stems (Exactech) 127Table 73: SWOT Novation Femoral Stems 127Table 74: Exactech Acetabular Systems (Exactech) 128Table 75: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 130Table 76: SWOT i-Hip Total Hip Implant 130Table 77: EcoFit Femoral Stem (Implantcast GMBH) 132Table 78: Aida Short Femoral Stem (Implantcast GMBH) 133Table 79: AJS Hip System (Implantcast GMBH) 135Table 80: DiaLoc Hip Stem (Implantcast GMBH) 137Table 81: LOAD SHIFT Hip Stem (Implantcast GMBH) 138Table 82: Ceraco Hip Stem (Implantcast GMBH) 139Table 83: IC Straight Stem Type I and Type II (Implantcast GMBH) 140Table 84: Bicana Hip Stem (Implantcast GMBH) 141Table 85: SWOT Implantcast GMBH Femoral Stems 142Table 86: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 144Table 87: Aeon Hip System (JRI Orthopaedics) 145Table 88: SWOT Aeon Hip System 146Table 89: Furlong Hip System and Evolution System (JRI Orthopaedics) 147Table 90: Clinical Studies Furlong Hip System (JRI Orthopaedics) 148Table 91: SWOT Furlong Hip System and Evolution System 148Table 92: Limacorporate Cementless Femoral Stems (Limacorporate SPA) 150Table 93: SWOT Limacorporate Cementless Femoral Stems 150Table 94: Cemented and Cementless Stems (Limacorporate SPA) 152Table 95: SWOT Cemented and Cementless Stems (Limacorporate SPA) 152Table 96: Limacorporate Acetabular Systems 153Table 97: Cemented and Cementless Stems (Medacta) 155Table 98: SWOT Medacta Stems 155Table 99: Acetabular Cups and Femoral Heads (Medacta) 156Table 100: Helicon Hip System (TGM Medical, wholly owned by Medtronic) 158Table 101: SWOT Helicon Hip System 158Table 102: Vektor Titan and Vektor CoCr (Peter Brehm GMBH) 160Table 103: Clinical Studies Peter Brehm Stems (Peter Brehm GMBH) 160Table 104: SWOT Peter Brehm Products 161Table 105: Libra and Sagittal EVL (Serf Dedienne Santé) 163Table 106: SWOT Libra and Sagittal EVL 163Table 107: Acetabular Cups (Serf Dedienne Santé) 165Table 108: Echelon and Synergy (Smith & Nephew) 167Table 109: SWOT Echelon and Synergy 167Table 110: Anthology Hip System (Smith & Nephew) 168Table 111: SWOT Anthology Hip System 169Table 112: CPCS and Spectron Hip System (Smith & Nephew) 170Table 113: SWOT CPCS and Spectron Hip System 170Table 114: Emperion and SMF Modular Stems (Smith & Nephew) 171Table 115: SWOT Emperion and SMF Modular Stems 172Table 116: Acetabular Cups (Smith & Nephew) 173Table 117: ProClass Hip Stem (Stelkast) 174Table 118: SWOT ProClass Hip Stem 174Table 119: Progeny Hip Stem (Stelkast) 175Table 120: SWOT Progeny Hip Stem 176Table 121: Protract Hip Stem (Stelkast) 177Table 122: SWOT Protract Hip Stem 177Table 123: Provident Hip Stem (Stelkast) 178Table 124: SWOT Provident Hip Stem 179Table 125: Acetabular Cups (Stelkast) 181Table 126: Cementless Stems (Stryker) 183Table 127: SWOT Cementless Stems 183Table 128: Cemented Stems (Stryker) 184Table 129: SWOT Cemented Stems 185Table 130: Acetabular Systems (Stryker) 187Table 131: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) 188Table 132: SWOT Diamond Total Hip Implant 189Table 133: Linea Stem (Tornier N.V.) 191Table 134: SWOT Linea Stem 192Table 135: Meije Duo Stem (Tornier N.V.) 193Table 136: SWOT Meije Duo Stem 194Table 137: Oceane Stem (Tornier N.V.) 195Table 138: SWOT Oceane Stem 196Table 139: Tornier Femoral Heads (Tornier N.V.) 197Table 140: Oceane Cup (Tornier N.V.) 198Table 141: Tornier Dynacup (Tornier N.V.) 199Table 142: Tornier Dual Mobility (Tornier N.V.) 200Table 143: Perfecta Cementless and Cemented Stems (Wright Medical) 201Table 144: SWOT Perfecta Cementless and Cemented Stems 202Table 145: Cementless Femoral Stems (Wright Medical) 204Table 146: SWOT Cementless Femoral Stems 205Table 147: Cemented Femoral Stems (Wright Medical) 206Table 148: SWOT Cemented and Cementless Femoral Stems (Wright Medical) 207Table 149: Acetabular Systems (Wright Medical) 209Table 150: UTF and UTF Reduced Stem (United Orthopedic Company) 211Table 151: SWOT UTF and UTF Reduced Stem 211Table 152: Hip U1 and U2 Stems (United Orthopedic Corporation) 212Table 153: SWOT Acetabular Systems (United Orthopedic Corporation) 213Table 154: Acetabular Systems (United Orthopedic Corporation) 214Table 155: Press-Fit Stems (Zimmer Holdings Inc.) 216Table 156: SWOT Press-Fit Stems 216Table 157: Acetabular Systems (Zimmer Holdings Inc.) 218Table 158: Exactech LPI Prime Hip System (Exactech) 232Table 159: Regulatory Differences Between the US and EU 238Table 160: Company Profile – B. Braun 250Table 161: B. Braun Product Portfolio 251Table 162: SWOT Analysis – B. Braun 251Table 163: Company Profile – Biomet Orthopedics 252Table 164: Biomet Product Portfolio 254Table 165: SWOT Analysis – Biomet Orthopedics 256Table 166: Company Profile – Corentec Co. Ltd. 257Table 167: Corentec Product Portfolio 257Table 168: SWOT Analysis – Corentec Co. Ltd. 258Table 169: Company Profile – Corin Group 259Table 170: Corin Group Product Portfolio 260Table 171: SWOT Analysis – Corin Group 260Table 172: Company Profile – DePuy Synthes International 262Table 173: DePuy Synthes International Product Portfolio 262Table 175: Company Profile – Exactech 266Table 176: Exactech Product Portfolio 267Table 177: SWOT Analysis – Exactech 268Table 178: Company Profile – Iconacy Orthopedic Implants LLC 269Table 179: Iconacy Orthopedic Implants LLC Product Portfolio 269Table 180: SWOT Analysis – Iconacy Orthopedic Implants LLC 270Table 181: Company Profile – Implantcast GMBH 271Table 182: Implantcast GMBH Product Portfolio 272Table 183: SWOT Analysis – Implantcast GMBH 273Table 184: Company Profile – JRI Orthopaedics 274Table 185: JRI Orthopaedics Product Portfolio 275Table 186: SWOT Analysis – JRI Orthopaedics 276Table 187: Company Profile – KYOCERA Medical Corporation 277Table 188: KYOCERA Medical Corporation Product Portfolio 278Table 189: SWOT Analysis – KYOCERA Medical Corporation 279Table 190: Company Profile – Limacorporate S.P.A 280Table 191: Limacorporate S.P.A Product Portfolio 281Table 192: SWOT Analysis – Limacorporate S.P.A 282Table 193: Company Profile – Medacta International 283Table 194: Medacta International Product Portfolio 284Table 195: SWOT Analysis – Medacta International 285Table 196: Company Profile – Medtronic 286Table 197: Medtronic Product Portfolio 287Table 198: SWOT Analysis – Medtronic 287Table 199: Company Profile – NovoSource Inc. 288Table 200: NovoSource Inc. Product Portfolio 288Table 201: SWOT Analysis – NovoSource Inc. 289Table 202: Company Profile – Peter Brehm GMBH 289Table 203: Peter Brehm GMBH Product Portfolio 290Table 204: SWOT Analysis – Peter Brehm GMBH 290Table 205: Company Profile – Serf Dedienne Santé 291Table 206: Serf Dedienne Santé Product Portfolio 292Table 207: SWOT Analysis – Serf Dedienne Santé 293Table 208: Company Profile – Smith & Nephew 294Table 209: Smith & Nephew Product Portfolio 295Table 210: SWOT Analysis – Smith & Nephew 296Table 211: Company Profile – Stelkast 297Table 212: Stelkast Product Portfolio 298Table 213: SWOT Analysis – Stelkast 298Table 214: Company Profile – Stryker 300Table 215: Stryker Product Portfolio 301Table 216: SWOT Analysis – Stryker 302Table 217: Company Profile – Tianjin Zhengtian Medical Instrument Co. Ltd. 303Table 218: Tianjin Zhengtian Medical Instrument Co. Ltd. Product Portfolio 304Table 219: SWOT Analysis – Tianjin Zhengtian Medical Instrument Co. Ltd. 304Table 220: Company Profile – Tornier N.V. 306Table 221: Tornier N.V. Product Portfolio 307Table 222: SWOT Analysis – Tornier N.V. 308Table 223: Company Profile – Wright Medical 309Table 224: Wright Medical Product Portfolio 310Table 225: SWOT Analysis – Wright Medical 312Table 226: Company Profile – United Orthopedic Corporation 313Table 227: United Orthopedic Corporation Product Portfolio 314Table 228: SWOT Analysis – United Orthopedic Corporation 314Table 229: Company Profile – Zimmer Holdings Inc. 316Table 230: Zimmer Holdings Inc. Product Portfolio 317Table 231: SWOT Analysis – Zimmer Holdings, Inc. 318Table 232: Other Companies in the Global Hip Replacement Market 319Table 233: EU Sales ($m) Forecast for THR, 2010–2019 332Table 234: France Sales ($m) Forecast for THR, 2010–2019 337Table 235: Germany Sales ($m) Forecast for THR, 2010–2019 339Table 236: Italy Sales ($m) Forecast for THR, 2010–2019 340Table 237: Spain Sales ($m) Forecast for THR, 2010–2019 342Table 238: UK Sales ($m) Forecast for THR, 2010–2019 344 1.2 List of FiguresFigure 1: Anatomy of the Hip 33Figure 2: Treatment Paradigm for Hip Osteoarthritis 40Figure 3: Treatment Paradigm for Hip Fractures 41Figure 4: Hip Arthrodesis 43Figure 5: Partial Hip Arthroplasty and Total Hip Arthroplasty 47Figure 6: Surgical Approach Used by Orthopedic Surgeons Globally 51Figure 7: Population with Osteoarthritis in the EU, 2010–2019 58Figure 8: EU Costs Related to Total Hip Replacement Procedure 61Figure 9: Global Market Share for Reconstructive Products, 2012 63Figure 10: Cementless, Cemented, Hybrid Product Usage by Orthopedic Surgeons, by Country 65Figure 11: Bicontact Universal Hip System (B. Braun) 66Figure 12: Excia Hip Stem (B. Braun) 70Figure 13: Metha® Short Hip Stem (B. Braun) 73Figure 14: TRJ Cementless Hip Endoprosthesis System (B. Braun) 76Figure 15: Plasmacup SC Acetabular Cup (B. Braun) 79Figure 16: Balance Femoral Component (Biomet) 80Figure 17: Bi-Metric Femoral Components (Biomet) 82Figure 18: Bio-Moore II Hip System (Biomet) 84Figure 19: Generation 4 Polished Hip System (Biomet) 87Figure 20: Integral Porous Primary Hip System (Biomet) 88Figure 21: Mallory Femoral Component (Biomet) 91Figure 22: Progressive Total Hip System (Biomet) 93Figure 23: Rx 90 Smooth Primary Femoral Component (Biomet) 94Figure 24: Stanmore Hip System (Biomet) 96Figure 25: Taperloc and Balance Microplasty Hip Stems (Biomet) 98Figure 26: Bencox Stems (Corentec Co. Ltd) 102Figure 27: Bencox Acetabular Systems (Corentec Co. Ltd.) 105Figure 28: MetaFix (Corin) 106Figure 29: MiniHip (Corin) 108Figure 30: MRP-Titan (Corin) 110Figure 31: TaperFit (Corin) 112Figure 32: Trinity Acetabular System (Corin) 114Figure 33: Cenator Acetabular Cup (Corin) 116Figure 34: Cementless Systems (DePuy Synthes) 117Figure 35: Cemented Systems (DePuy Synthes) 119Figure 36: DePuy Acetabular Systems (DePuy Synthes) 121Figure 37: AcuMatch Femoral Stems (Exactech) 123Figure 38: Novation Femoral Stems (Exactech) 126Figure 39: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 130Figure 40: EcoFit Femoral Stem (Implantcast GMBH) 132Figure 41: Aida Short Femoral Stem (Implantcast GMBH) 134Figure 42: AJS Hip System (Implantcast GMBH) 135Figure 43: DiaLoc Hip Stem (Implantcast GMBH) 137Figure 44: LOAD SHIFT Hip Stem (Implantcast GMBH) 139Figure 45: Ceraco Hip Stem (Implantcast GMBH) 140Figure 46: IC Straight Stem Type I and Type II (Implantcast GMBH) 141Figure 47: Bicana Hip Stem (Implantcast GMBH) 142Figure 48: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 144Figure 49: Aeon Hip System (JRI Orthopaedics) 146Figure 50: Furlong Hip System and Evolution System (JRI Orthopaedics) 148Figure 51: Cemented and Cementless Stems (Limacorporate SPA) 152Figure 52: Cemented and Cementless Stems (Medacta) 155Figure 53: Helicon Hip System (TGM Medical wholly owned by Medtronic) 158Figure 54: Vektor-Titan and Vektor-CoCr (Peter Brehm GMBH) 160Figure 55: Libra and Sagitta EVL (Serf Dedienne Santé) 163Figure 56: Acetabular Cups (Serf Dedienne Santé) 165Figure 57: Echelon and Synergy (Smith & Nephew) 167Figure 58: Anthology Hip System (Smith & Nephew) 169Figure 59: CPCS and Spectron Hip System (Smith & Nephew) 170Figure 60: Emperion and SMF Modular Stems (Smith & Nephew) 172Figure 61: Acetabular Cups (Smith & Nephew) 173Figure 62: ProClass Hip Stem (Stelkast) 174Figure 63: Progeny Hip Stem (Stelkast) 176Figure 64: Protract Hip Stem (Stelkast) 177Figure 65: Provident Hip Stem (Stelkast) 179Figure 66: Acetabular Systems (Stelkast) 181Figure 67: Cementless Stems (Stryker) 183Figure 68: Cemented Stems (Stryker) 185Figure 69: Acetabular Systems (Stryker) 187Figure 70: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) 189Figure 71: Linea Stem (Tornier N.V.) 191Figure 72: Meije Duo Stem (Tornier N.V.) 193Figure 73: Oceane Stem (Tornier N.V.) 195Figure 74: Tornier Femoral Heads (Tornier N.V.) 197Figure 75: Oceane Cup (Tornier N.V.) 198Figure 76: Tornier Dynacup (Tornier N.V.) 200Figure 77: Tornier Dual Mobility (Tornier N.V.) 201Figure 78: Perfecta Cementless and Cemented Stems (Wright Medical) 202Figure 79: Cementless Femoral Stems (Wright Medical) 204Figure 80: Profemur Gladiator (Wright Medical) 207Figure 81: Acetabular Systems (Wright Medical) 209Figure 82: UTF and UTF Reduced Stem (United Orthopedic Corporation) 211Figure 83: Hip U1 and U2 Stems (United Orthopedic Corporation) 213Figure 84: Acetabular Systems (United Orthopedic Corporation) 215Figure 85: Press-Fit Stems (Zimmer Holdings Inc.) 216Figure 86: Acetabular Systems (Zimmer Holdings Inc.) 218Figure 87: Europe Primary Hip Arthroplasty Procedure Volumes (2010–2019) 237Figure 88: EU Sales ($m) Forecast for THR, 2010–2019 334Figure 89: THR Revenue by Major Market, 2012 and 2019 335Figure 90: THR Revision Surgery Revenue by Major Market, 2010 and 2019 336Figure 91: France Sales ($m) Forecast for THR, 2010–2019 339Figure 92: Germany Sales ($m) Forecast for THR, 2010–2019 340Figure 93: Italy Sales ($m) Forecast for THR, 2010–2019 342Figure 94: Spain Sales ($m) Forecast for THR, 2010–2019 343Figure 95: UK Sales ($m) Forecast for THR, 2010–2019 345 Companies MentionedB. Braun Biomet OrthopedicsCorentec Co. Ltd.Corin DePuy Synthes InternationalExactech Iconacy Orthopedic Implants LLCImplantcast GMBHJRI OrthopaedicsKyocera Limacorporate S.P.AMedacta Medtronic NovoSource Inc.Peter Brehm GMBHSerf Dedienne S To order this report: MediPoint: Total Hip Replacement - EU Analysis and Market Forecasts http://www.reportlinker.com/p01623040/MediPoint-Total-Hip-Replacement---EU-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,113.54 +61.81 0.36%
S&P 500 1,983.53 +9.90 0.50%
NASDAQ 4,456.0160 +31.3120 0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs